Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome.
Goodnick, P J, Sandoval, R, Brickman, A et al. · Biological psychiatry · 1992 · DOI
Quick Summary
This study tested whether bupropion, an antidepressant medication, could help ME/CFS patients who didn't benefit from or couldn't tolerate fluoxetine (another antidepressant). Nine patients took 300 mg of bupropion daily for 8 weeks and showed significant improvement in depression symptoms. The researchers also found that bupropion appeared to affect certain brain chemicals and immune markers in ways that correlated with symptom improvement.
Why It Matters
This study addresses a clinically important problem—ME/CFS patients who don't respond to first-line antidepressants—and suggests bupropion may be an effective alternative. The mechanistic findings linking symptom improvement to specific neurochemical and immune markers provide potential biomarkers for treatment response and insights into ME/CFS pathophysiology.
Observed Findings
Significant improvement in HDRS scores with bupropion 300 mg/day over 8 weeks (t=4.80, p<0.01)
Significant improvement in BDI scores (t=2.48, p<0.05)
Strong correlation between HDRS improvement and increased plasma HVA (r=0.96, p<0.01)
Significant elevation in total plasma MHPG during treatment (t=2.37, p=0.05)
Decreased T1 microsomal antibodies and inverse correlation between NK cell increases and free MHPG changes (r=-0.88, p<0.05)
Inferred Conclusions
Bupropion is an effective alternative for CFS patients who do not tolerate or respond to fluoxetine
Bupropion's therapeutic effects may be mediated through dopaminergic pathways, as evidenced by HVA and MHPG changes
Trough blood levels above 30 ng/ml may be necessary for clinical response
Immunomodulatory effects accompany neurochemical changes during bupropion treatment
Remaining Questions
How do these findings generalize to larger, more diverse CFS populations, and would a placebo-controlled design confirm efficacy?
Which baseline characteristics predict bupropion response, and can HVA or MHPG levels serve as biomarkers for treatment selection?
What This Study Does Not Prove
This study does not establish that dopamine dysregulation is the primary cause of ME/CFS, only that bupropion-induced changes in dopamine-related compounds correlate with symptom improvement in some patients. The open-label design means results may reflect placebo response, observer bias, or natural fluctuation rather than true drug effect. The small sample size (n=9) limits generalizability, and findings may not apply to all ME/CFS patients or those who tolerate fluoxetine.
Tags
Symptom:Cognitive DysfunctionFatigue
Biomarker:MetabolomicsBlood Biomarker
Method Flag:PEM Not DefinedNo ControlsSmall SampleExploratory Only